Monte Rosa Therapeutics, Inc. (GLUE)
NASDAQ: GLUE · Real-Time Price · USD
22.84
-0.18 (-0.78%)
At close: Jan 23, 2026, 4:00 PM EST
22.80
-0.04 (-0.18%)
After-hours: Jan 23, 2026, 7:43 PM EST
Monte Rosa Therapeutics Stock Forecast
Stock Price Forecast
The 4 analysts that cover Monte Rosa Therapeutics stock have a consensus rating of "Strong Buy" and an average price target of $29.5, which forecasts a 29.16% increase in the stock price over the next year. The lowest target is $17 and the highest is $37.
Price Target: $29.5 (+29.16%)
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Monte Rosa Therapeutics stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Aug '25 | Sep '25 | Oct '25 | Nov '25 | Dec '25 | Jan '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 0 | 0 | 0 | 0 | 0 | 1 |
| Buy | 2 | 2 | 2 | 1 | 2 | 3 |
| Hold | 1 | 1 | 1 | 1 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 3 | 3 | 3 | 2 | 2 | 4 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Piper Sandler | Piper Sandler | Buy Reiterates $28 → $37 | Buy | Reiterates | $28 → $37 | +62.00% | Jan 14, 2026 |
| Wells Fargo | Wells Fargo | Buy Maintains $22 → $30 | Buy | Maintains | $22 → $30 | +31.35% | Jan 8, 2026 |
| Guggenheim | Guggenheim | Strong Buy Maintains $16 → $34 | Strong Buy | Maintains | $16 → $34 | +48.86% | Jan 8, 2026 |
| Wells Fargo | Wells Fargo | Hold → Buy Upgrades $13 → $22 | Hold → Buy | Upgrades | $13 → $22 | -3.68% | Dec 16, 2025 |
| Wells Fargo | Wells Fargo | Hold Maintains $10 → $13 | Hold | Maintains | $10 → $13 | -43.08% | Nov 7, 2025 |
Financial Forecast
Revenue This Year
139.16M
from 75.62M
Increased by 84.02%
Revenue Next Year
56.84M
from 139.16M
Decreased by -59.16%
EPS This Year
-0.28
from -0.98
EPS Next Year
-1.30
from -0.28
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | 169.0M | 200.6M | ||||
| Avg | 139.2M | 56.8M | ||||
| Low | 118.6M | n/a |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | 123.4% | 44.1% | ||||
| Avg | 84.0% | -59.2% | ||||
| Low | 56.8% | - |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | 0.04 | 0.26 | ||||
| Avg | -0.28 | -1.30 | ||||
| Low | -0.44 | -1.93 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | - | - | ||||
| Avg | - | - | ||||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.